1. Generics Bulletin
  2. >>Preview

What’s Next? Five Things To Look Out For In February

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

What's Next Image
Source: Norstella

The floodgates are due to open for US biosimilar competition to Stelara (ustekinumab) in February, with a multitude of ustekinumab biosimilars that have received US Food and Drug Administration approval set to launch under the terms of patent-litigation settlement agreements.

Partners Alvotech and Teva – which gained approval for their Selarsdi (ustekinumab-aekn) version in April –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Preview

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What’s Next? Five Things To Look Out For In April

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

What’s Next? Five Things To Look Out For In March

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

What’s Next? Five Things To Look Out For In February

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

More from Biosimilars

Formycon Snatches Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By Dave Wallace

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By Dean Rudge

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.